CD11b

Background

CD11b (CR3, Mac-1, αMβ2) is a critical immunoregulatory molecule primarily expressed on the surface of white blood cells such as neutrophils, monocytes, and macrophages. As a part of the integrin αMβ2 complex, CD11b plays a crucial role in white blood cells' adhesion, migration, and phagocytosis, regulating immune and inflammatory responses. It is significantly involved in various inflammatory diseases, infections, and cancers, making it a potential target for therapeutic and immunomodulatory interventions. Targeting CD11b with antibodies and small molecule inhibitors can modulate its functions for treating and researching related diseases.

Its Gene ID: 3684, UniProtKB ID: P11215, and OMIM ID: 120980.

Fig.1 The structure and function of CD11b.^{1, 4}

CD11b in Diseases

CD11b is closely associated with various diseases, making it an essential target for research and clinical treatment. In inflammatory diseases like rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease, CD11b is highly expressed and facilitates leukocyte migration and local inflammatory responses. In bacterial and viral infections, CD11b mediates leukocyte adhesion and migration, helping to clear pathogens. In cancer, CD11b⁺ tumor-associated macrophages (TAMs) promote tumor growth and immune suppression, while in acute myeloid leukemia, high CD11b expression is associated with disease aggressiveness. In autoimmune conditions like multiple sclerosis and psoriasis, CD11b⁺ cells are involved in neuroinflammation and skin inflammation. Developing monoclonal antibodies and small molecule inhibitors targeting CD11b can specifically block its function for treating related diseases. CD11b expression levels can also serve as diagnostic and prognostic markers for certain diseases. In-depth research into the mechanisms of CD11b in various diseases will provide new approaches for disease diagnosis, treatment, and prevention.

Fig.2 An oncogenic role for CD11b during colorectal cancer (CRC).^{2, 4}

CD11b Antibodies

As a critical immunoregulatory molecule, CD11b is significant in basic research and provides a potential target for diagnosing and treating various diseases. Monoclonal antibodies targeting CD11b can block its function, serving as treatments for specific inflammatory diseases and cancers. For instance, anti-CD11b antibodies can reduce inflammatory responses or enhance anti-tumor immunity.

CD11b Functional Service

Creative Biolabs offers an extensive selection of CD11b-associated products, including ELISA assay kits, anti-CD11b antibodies, human complement CD11b proteins, CD11b blocking peptides, and CD11b inhibitors. These tools are proficient in accurately detecting and monitoring the interplay between antibody domains and the human CD11b protein, thereby serving as essential resources in research aimed at developing disease therapies.

Fig.3 Expression of CD11b on bone marrow-derived immune cells.^{3, 4}

CD11b, expressed on bone marrow-derived immune cells, plays a vital role in regulating leukocyte adhesion and migration. Researchers utilized CD11b knockout mice and an Apc^Min/+ intestinal adenoma model to elucidate CD11b’s role in intestinal tumorigenesis. Increased infiltration of CD11b⁺ myeloid cells in tumor tissues compared to non-cancerous tissues was observed in CRC patients, as identified via immunofluorescence. Findings indicate that CD11b deficiency impedes myeloid cell trafficking to the tumor microenvironment, suppressing the Wnt/β-catenin pathway and tumor growth. This study underscores CD11b’s potential as an oncogene and its promise as a therapeutic target in CRC.

Creative Biolabs offers a comprehensive suite of services centered on CD11b functionality, including specialized assays for CD11b interactions and tailored functional assessments. These meticulously crafted solutions are designed to support clients in advancing their clinical and research projects. In addition, we provide extensive anti-CD11b antibody services, from antigen design and production to antibody purification and characterization. Our ready-to-use anti-CD11b antibodies are rigorously tested for applications such as western blotting, immunohistochemistry, and flow cytometry. Furthermore, the company offers antibody labeling and conjugation with diverse tags like fluorescent dyes, enzymes, and biotin, catering to a variety of experimental needs.

References

1. Lamers, Christina, Carla Johanna Plüss, and Daniel Ricklin. "The promiscuous profile of complement receptor 3 in ligand binding, immune modulation, and pathophysiology." Frontiers in immunology 12 (2021): 662164.
2. Zhang, Qian-Qian, et al. "CD11b deficiency suppresses intestinal tumor growth by reducing myeloid cell recruitment." Scientific Reports 5.1 (2015): 15948.
3. Zhang, Qian-Qian, et al. "CD11b deficiency suppresses intestinal tumor growth by reducing myeloid cell recruitment." Scientific Reports 5.1 (2015): 15948.
4. Distributed under Open Access license CC BY 4.0, without modification.